Sleman Khoury, MD
Endocrinology, Diabetes & Metabolism · Southgate, MINPI 1578543849
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 28.3% of the total. Reporting peaked in 2019 at $37,198 and has fallen 82.9% since, to $6,357 in 2025. Among endocrinology, diabetes & metabolism clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,366 payments — averaging $46.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$18K
- Johnson & Johnson$12K
- Novo Nordisk$9K
- Lilly USA, LLC$3K
- Ascendis Pharma Endocrinology Inc$3K
- Amgen$2K
- plus $16K from 54 others
What the payments were for
- Consulting fees$1,4852%
- Speaking & faculty fees$32,87752%
- Travel & lodging$2,5324%
- Food & beverage$26,27542%
- Education$570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$12,512
- INVOKANA$11,730
- TOUJEO$8,726
- Tresiba$5,317
- Yorvipath$1,989
- Victoza$1,485
- CeQur Simplicity$488
- Korlym$252
- EVENITY$232
- CRENESSITY$136
- FARXIGA$134
- TZIELD$130
- Kerendia$125
- Repatha$125
- MOUNJARO$125
- DISEASE STATE$125
- JARDIANCE$125
- TEPEZZA$124
- Creon$120
How this compares
$63,225 in reported general payments places this provider in the 90th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 261 | $538,103 |
| JardianceEmpagliflozin | 277 | $384,540 |
| TrulicityDulaglutide | 117 | $240,176 |
| RybelsusSemaglutide | 51 | $118,783 |
| JanuviaSitagliptin Phosphate | 100 | $117,408 |
| FarxigaDapagliflozin Propanediol | 84 | $104,608 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 23 | $96,821 |
| Somatuline DepotLanreotide Acetate | 12 | $94,596 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 247 | $70,445 |
| Humalog Kwikpen U-100Insulin Lispro | 134 | $68,491 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $68,123 |
| MounjaroTirzepatide | 47 | $64,722 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $60,925 |
| Novolog FlexpenInsulin Aspart | 123 | $53,765 |
| Cinacalcet Hcl | 43 | $23,888 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $9,418 | $669,382337 claims |
| Boehringer IngelheimJardiance, Glyxambi | $1,507 | $403,003288 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $3,180 | $304,898164 claims |
| MerckJanuvia | $304 | $117,408100 claims |
| AstraZenecaFarxiga | $1,216 | $104,60884 claims |
| Ipsen Biopharmaceuticals, IncSomatuline Depot | $62 | $94,59612 claims |
| Johnson & JohnsonInvokana | $12,238 | $20,68213 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $501 | $15,7691,279 claims |
| Sanofi-aventis U.S. LLCLantus | $17,905 | $6,13922 claims |
| AbbVieSynthroid | $847 | $4,28273 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Southgate
- Nadia KhourySouthgate$33K
- Lowell SchmeltzFarmington Hills$1.3M
- George GrunbergerBloomfield Hills$931K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Jamal HammoudFlint$386K
- Abdulsalam Al KassabRochester Hills$351K
- Richard AuchusAnn Arbor$250K
- Eric LangerSterling Heights$213K
- Ashish VermaShelby Twp$179K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.